Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Acambis has extended its ChimeriVax-JE vaccine licensing agreement with Sanofi Pasteur, the vaccines division of the Sanofi-Aventis Group, to include India and the Indian subcontinent.
Subscribe to our email newsletter
Acambis will receive from Sanofi Pasteur an upfront payment, a milestone payment on licensure of the vaccine in India and royalties on sales in these territories. Bharat Biotech has made a significant contribution towards the development of ChimeriVax-JE (Japanese encephalitis) and Acambis has agreed to compensate Bharat Biotech. As with the existing agreement, Acambis will supply bulk ChimeriVax-JE vaccine to Sanofi Pasteur from its Canton, Massachusetts facility.
Ian Garland, CEO of Acambis, said: “This extended agreement will enable both Acambis and Sanofi Pasteur to benefit from a more co-ordinated approach in the JE endemic region. ChimeriVaxTM-JE is an important vaccine for a devastating disease and we are keen to progress towards licensure as quickly as possible.”